Cellular senescence and cancer

Journal of Pathology

Volumn 187, Issue 1, 1999, Pages 100-111

  Wynford Thomas, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Cancer; Cell cycle; Cyclin; Immortalization; p53; Senescence; Telomerase; Telomeres; Tumour suppressor gene

Indexed keywords

PROTEIN P21; PROTEIN P53; TELOMERASE;

BREAST CANCER; CANCER; CELL CYCLE; CELL DIVISION; CELL IMMORTALIZATION; CELL PROLIFERATION; DNA REPLICATION; GENETIC VARIABILITY; PRIORITY JOURNAL; REVIEW; SENESCENCE; TELOMERE; TUMOR SUPPRESSOR GENE;

CELL AGING; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; TELOMERASE;

EID: 0032907528     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:1<100::AID-PATH236>3.0.CO;2-T     Document Type: Review

References (94)

1. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-636.
2. Campisi J. The biology of replicative senescence. Eur J Cancer 1997; 33: 703-709.
3. Faragher R, Kipling D. How might replicative senescence contribute to human ageing? Bioessays (in press).
4. Rubin H. Telomerase and cellular lifespan: ending the debate? Nat Biotechnol 1998; 16: 396-397.
5. Thomas E, Al-Baker E, Dropcova S, et al. Different kinetics of senescence in human fibroblasts and peritoneal mesothelial cells. Exp Cell Res 1997; 236: 355-358.
6. Brooks RF, Richmond FN, Riddle PN, Richmond KM. Apparent heterogeneity in the response of quiescent Swiss 3T3 cells to serum growth factors: implications for the transition probability model and parallels with 'cellular senescence' and 'competence'. J Cell Physiol 1984; 121: 341-350.
7. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973; 41: 181-190.
8. Kipling D, The Telomere. Oxford: Oxford University Press, 1995.
9. Morin GB. The implications of telomerase biochemistry for human disease. Eur J Cancer 1997; 33: 750-760.
10. Wright WE, Shay JW. Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995; 5: 293-297.
11. de Lange T. Activation of telomerase in a human tumour. Proc Natl Acad Sci USA 1994; 91: 2882-2885.
12. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev 1995; 5: 249-255.
13. Wynford-Thomas D, Bond JA, Wylie FS, Jones CJ. Does telomere shortening drive selection for p53 mutation in human cancer? Mol Carcinogen 1995; 12: 119-123.
14. Bodnar AG, Ouellette M, Frolkis M. et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-352.
15. Kipling D, Cooke HJ. Hypervariable ultra-long telomeres in mice. Nature 1990; 347: 400-402.
16. Wynford-Thomas D. In vitro models of thyroid cancer. Cancer Surv 1993; 16: 115-133.
17. Kang MK, Guo W, Park NH. Replicative senescence of normal human oral keratinocytes is associated with the loss of telomerase activity without shortening of telomeres. Cell Growth Diff 1998; 9: 85-95.
18. Belair CD, Yeager TR, Lopez PM, Reznikoff CA. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci USA 1997; 94: 13 677-13 682.
19. Holliday R. Endless quest. Bioessays 1996; 18: 3-5.
20. von Zglinicki T, Saretzki G, Docke W, Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence? Exp Cell Res 1995; 220: 186-193.
21. Bond JA, Wyllie FS, Wynford-Thomas D. Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene 1994; 9: 1885-1889.
22. Rogan EM, Bryan TM, Hukku B, et al. Alterations in p53 and p16ink4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995; 15: 4745-4753.
23. Aladja P, Wong H, Garkavtsev I, Geillette C, Riabowol K. Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci USA 1995; 92: 8348-8352.
24. Bond J, Haughton M, Blaydes J, Gire V, Wynford-Thomas D, Wyllie F. Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. Oncogene 1996; 13: 2097-2104.
25. Vaziri H, West MD, Allsopp RC, et al. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J 1997; 16: 6018-6033.
26. Garkavtsev I, Riabowol K. Extension of the replicative lifespan of human diploid fibroblasts by inhibition of the p33ING1 candidate tumour suppressor. Mol Cell Biol 1997; 17: 2014-2019.
27. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-734.
28. Blaydes JP, Wynford-Thomas D. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene 1998; 16: 3317-3322.
29. Gire V, Wynford-Thomas D. Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol Cell Biol 1998; 18: 1611-1621.
30. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994: 211: 90-98.
31. Brown JP, Wenyi W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997; 277: 831-834
32. Bond JA, Blaydes JP, Rowson J, et al. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SD11/WAF1. Cancer Res 1995; 55: 2404-2409.
33. Tahara T, Sato E, Noda A, Ide T. Increase in expression level of p21sdi1/ cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene 1995; 10: 835-840.
34. Goldstein S, Moerman EJ, Baxter RC. Accumulation of insulin-like growth factor binding protein-3 in conditioned medium of human fibroblasts increases with chronologic age of donor and senescence in vitro. J Cell Physiol 1993; 156: 294-302.
35. Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-649.
36. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 1996; 93: 13742-13747.
37. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996; 16: 859-867.
38. Robles SJ, Adami GR. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 1998; 16: 1113-1123.
39. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996; 68: 67-108.
40. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalisation of normal human diploid fibroblasts. Mol Cell Biol 1989; 9: 3088-3092.
41. Counter CM, Avillion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11: 1921-1929.
42. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92: 401-413.
43. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumours and tumour-derived cell lines. Nature Med 1997; 3: 1271-1274.
44. Bond J, Haughton M, Rowson J, Gire V, Wynford-Thomas D, Wyllie F. Control of replicative lifespan in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol Cell Biol (submitted).
45. McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998; 8: 351-354.
46. Vogt M, Haggblom C, Yeargin J, Christiansen-Weber T, Haas M. Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. Cell Growth Diff 1998; 9: 139-146.
47. Pereira-Smith OM, Smith JR. Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc Natl Acad Sci USA 1988; 85: 6042-6046.
48. Whitaker NJ, Bryan TM, Bonnefin P, et al. Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. Oncogene 1995; 11: 971-976.
49. Banga SS, Kim S, Hubbard K, et al. SEN6, a locus for SV40-mediated immortalization of human cells, maps to 6q26 27. Oncogene 1997; 14: 313-321.
50. Loughran O, Clark LJ, Bond J, et al. Evidence for the inactivation of multiple replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes. Oncogene 1997; 14: 1955-1964.
51. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14: 4240-4248.
52. Shay JW, Wright WE, Brasiskyte D, Van der Hagen BA. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalisation in human mammary epithelial cells but not human fibroblasts. Oncogene 1993; 8: 1407-1413.
53. Foster SA, Wong DJ, Barrett MT, Galloway DA. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 1998; 18: 179-1801.
54. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 1998; 17: 199-205.
55. Stampfer MR, Yaswen P. Culture systems for study of human mammary epithelial cell proliferation, differentiation and transformation. Cancer Surv 1993; 18: 7-34.
56. Foster SA, Galloway DA. Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells. Oncogene 1996; 12: 1773-1779.
57. Wazer DE, Liu X-L, Chu Q, Gao Q, Band V. Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc Natl Acad Sci USA 1995; 92: 3687-3691.
58. Band V. Preneoplasic transformation of human mammary epithelial cells. Semin Cancer Bull 1995; 6: 185-192.
59. Bond JA, Ness GO, Rowson J, Ivan M, White D, Wynford-Thomas D. Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression. Int J Cancer 1996; 67: 563-572.
60. Wyllie F, Lemoine N, Barton C, Dawson T, Bond J, Wynford-Thomas D. Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinogen 1993; 7: 83-88.
61. Wynford-Thomas D, Blaydes JP. The influence of cell context on the selection pressure for p53 mutation in human cancer. Carcinogenesis 1998; 19: 29-36.
62. Puthenveettil JA, Frederickson SM, Reznikoff CA. Apoptosis in human papillomavirus 16 E7-, but not E6-immortalized human uroepithelial cells. Oncogene 1996; 13: 1123-1131.
63. Paraskeva C, Einerty S, Powell S. Immortalization of a human colorectal adenoma cell line by continuous in vitro passage: possible involvement of chromosome 1 in tumour progression. Int J Cancer 1988; 41: 908-912.
64. Wynford-Thomas D. Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Hormone Res 1997; 47: 145-147.
65. Edington KG, Loughran OP, Berry IJ, Parkinson EK. Cellular immortality: a late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss. Mol Carcinogen 1995; 13: 254-265.
66. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D. In vitro reconstruction of tumour initiation in a human epithelium. Oncogene 1994; 9: 281-290.
67. Vojta PJ, Barrett JC. Genetic analysis of cellular senescence. Biochim Biophys Acta 1995; 1242: 29-41.
68. Sugrue MM, Shin DY, Lee SW, Aaronson SA. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci USA 1997; 94: 9648-9653.
69. Oshimura M, Barrett JC. Multiple pathways to cellular senescence: role of telomerase repressors. Eur J Cancer 1997; 33: 710-715.
70. Loughran O, Malliri A, Owens D, et al. Association of CDKN2A/ p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene 1996; 13: 561-568.
71. Williams DW, Williams ED. The pathology of follicular thyroid epithelial tumours. In: Wynford-Thomas D, Williams ED, eds. Thyroid Tumours; Molecular Basis of Pathogenesis. Edinburgh: Churchill Livingstone, 1989.
72. Wynford-Thomas D. Molecular genetics of thyroid cancer. Curr Opin Endoc Diab 1995; 2: 429-436.
73. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997; 88: 657-666.
74. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
75. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34.
76. Wyndford-Thomas D, Kipling D. Telomeres, cancer and the knockout mouse. Nature 1997; 389: 551-552.
77. Lee HW, Blasco MA, Gottlieb GJ, Horner JW III, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferate organs. Nature 1998; 392: 569-574.
78. DePinho R. Cancer and development in the telomerase RNA knockout mouse. In: Proceedings of Cellular Senescence. Oxford: Oriel College, 1998.
79. Harle-Bachor C, Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Prof Natl Acad Sci USA 1996; 93: 6476-6481.
80. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85: 2315-2320.
81. Kolquist KA, Ellisen LW, Counter CM, et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nature Genet 1998; 19: 182-186.
82. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995; 55: 2533-2536.
83. Greaves M. Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Trends Genet 1996; 12: 127-128.
84. Hastie DN, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346: 866-868.
85. Bacchetti S, Counter CM. Telomeres and telomerase in human cancer. Int J Oncol 1995; 7: 423-432.
86. Engelhardt M, Albannell J, Drullinsky P, et al. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon and sarcoma. Clin Cancer Res 1997; 3: 1849-1857.
87. Scales DK, Clark SK, Phillips RK, Venitt S. Lack of telomerase in desmoids occurring sporadically and in association with familial adenomatous polyposis. Br J Surg 1998; 85: 965-969.
88. Burger AM, Bibby MC, Double JA. Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy. Br J Cancer 1997; 75: 516-522.
89. Hiyama E, Yokoyama T, Hiyama K, et al. Alteration of telomeric repeat length in adult and childhood solid neoplasias. Int J Oncol 1995; 6: 13-16.
90. Hiyama E, Gollahon L, Kataoka T, et al. Telomerase activity in human breast tumours. J Natl Cancer Inst 1996; 88: 116-122.
91. Horikawa I, Oshimura M, Barrett JC. Repression of the telomerase catalytic subunit by a gene on human chromosome 3 that induces cellular senescence. Mol Carcinogen 1998; 22: 65-72.
92. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997; 385: 740-743.
93. Jones CJ, Soley A, Skinner JW, et al. Dissociation of telomere dynamics from telomerase activity in human thyroid cancer cells. Exp Cell Res 1998; 240: 333-339.
94. Greider CW. Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci USA 1998; 95: 90-92.